南方医科大学学报

南方医科大学学报 ›› 2019, Vol. 39 ›› Issue (03): 298-.doi: 10.12122/j.issn.1673-4254.2019.03.07

• • 上一篇    下一篇

地尔硫卓上调异黏蛋白在肝癌细胞中的表达

郭睿，金雪媛，田怡，黄小钟，李宗芳，杨军   

  • 出版日期:2019-03-20 发布日期:2019-03-20

Calcium channel blocker diltizem transiently inhibits migration and up-regulates metadherin expression in hepatocellular carcinoma cells in vitro

  • Online:2019-03-20 Published:2019-03-20

HTML

PDF

1573

摘要： 目的研究钙离子通道抑制剂逆转肝癌细胞多药耐药和对异黏蛋白表达的影响及分子机制。方法采用不同浓度钙离子 抑制剂（0、25、50、100、200、400 μmol/L）干预肝癌MHCC97H、7402细胞不同时间（12、24、48 h）后，用体外细胞划痕实验检测处 理后肝癌细胞运动迁徙能力；采用RT-PCR和免疫细胞化学技术检测钙离子抑制剂对肝癌细胞中P-gp和异黏蛋白的表达的影 响。结果钙离子抑制剂能够一过性抑制肝癌MHCC97H、7402 细胞的迁徙运动能力，且具有一定的时间和浓度依赖性特点 （P<0.05）。同时，不同浓度钙离子抑制剂盐酸地尔硫卓均能一过性上调肝癌MHCC97H、7402细胞中异黏蛋白mRNA和蛋白的 表达（P<0.05），但并不抑制P-gp蛋白的表达。结论钙离子抑制剂地尔硫卓能一过性抑制MHCC97H、7402肝癌细胞的迁徙运 动，并能反馈性上调促癌基因异黏蛋白mRNA和蛋白的表达水平。因而，采用钙离子抑制剂很可能具有增加肿瘤进展的潜在风险。

Abstract: Objective To investigate the effect of calcium channel blocker diltizem in reversing multi-drug resistance (MDR) and on metadherin expression in hepatocellular carcinoma cells and explore the molecular mechanism. Methods Hepatocellular carcinoma MHCC97H and 7402 cells were treated with diltiazem hydrochloride, a calcium channel blocker (0, 25, 50, 100, 200, and 400 μmol/L), for 12, 24, or 48 h. Wound healing assay was employed to assess the changes in the mobility and migration of the cells following the treatments, and the changes in the expression levels of metadherin mRNA and protein and P-gp protein were determined using RT-PCR and immunocytochemistry. Results Diltiazem hydrochloride could transiently inhibit the migration and movement of MHCC97H and 7402 cells in vitro in a time- and concentration-dependent manner (P<0.05). Diltiazem hydrochloride at different concentrations also transiently up-regulated the expressions of metadherin mRNA and protein but did not inhibit the expression of P-gp protein in MHCC97H and 7402 cells. Conclusion Calcium channel blocker can transiently inhibit the migration of hepatocellular carcinoma cells in vitro and up-regulate the expression of metadherin mRNA and protein through a feedback mechanism, suggesting the potential risk of calcium channel blockers for promoting tumor progression during the treatment of malignant tumors.